Allos Therapeutics Invites Investors to Listen to Webcast of Presentation at J.P. Morgan Healthcare Conference

WESTMINSTER, Colo.--(BUSINESS WIRE)-- Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, today announced that members of the Company’s senior management will present at the 29th Annual J.P. Morgan Healthcare Conference. Management will provide an overview of the Company, including a commercial update for FOLOTYN® (pralatrexate injection) in relapsed or refractory peripheral T-cell lymphoma, as well as an update on the Company’s plans for FOLOTYN in advanced non-small cell lung cancer.

The presentation will begin at 8:00 a.m. Pacific Time on Wednesday, January 12, 2011. There will be a live webcast of the presentation, which will be accessible through a link available on the home page and investor relations section of the Allos website. In addition, the webcast will be archived for 90 days.

About Allos Therapeutics

Allos is currently focused on the development and commercialization of FOLOTYN® (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Allos is also developing FOLOTYN in other hematologic malignancies and solid tumors. Allos retains exclusive worldwide rights to FOLOTYN for all indications. Allos is headquartered in Westminster, CO. For additional information, please visit

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Additional information concerning these forward-looking statements and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the presentation. All forward-looking statements are based on information currently available to the Company on the date thereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of these presentations, except as required by law.


for Allos Therapeutics, Inc.
Monique Greer, 720-540-5268
[email protected]
Aline Schimmel, 312-238-8957
[email protected]

KEYWORDS:   United States  North America  California  Colorado

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical